Introduction Phase 3 trials have shown comparable efficacy of direct oral anticoagulants
(DOACs) and vitamin K antagonists in patients with acute venous thromboembolism (VTE) …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Introduction Venous thromboembolism (VTE) is associated with a considerable risk for
morbidity and recurrence and related hospitalizations. In the Apixaban after the Initial …

The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban,
demonstrated in phase III trials, need to be confirmed in daily care. Using data from the …

Introduction Data from clinical trials indicate that direct oral anticoagulants (DOACs) are
noninferior and safer than conventional therapy (low-molecular-weight heparin followed by …

Introduction Patients at increased risk of bleeding and recurrent VTE who develop venous
thromboembolism (VTE) present challenges for clinical management. This study evaluated …

Abstract Abstract LBA-1 Background: Apixaban, an oral factor Xa inhibitor, may provide a
simple, fixed-dose regimen for extended treatment of venous thromboembolism. Objectives …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

In the AMPLIFY clinical trial, apixaban was non-inferior to warfarin plus subcutaneous
enoxaparin bridge therapy in the treatment of acute venous thromboembolism (VTE) and …

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …